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Abstract
Background
To date, several clinical laboratory parameters associated with Coronavirus disease 2019
(COVID-19) severity have been reported. However, these parameters have not been
observed consistently across studies. The aim of this review was to assess clinical labora-
tory parameters which may serve as markers or predictors of severe or critical COVID-19.
Methods and findings
We conducted a systematic search of MEDLINE, Embase, Web of Science, CINAHL and
Google Scholar databases from 2019 through April 18, 2020, and reviewed bibliographies
of eligible studies, relevant systematic reviews, and the medRxiv pre-print server. We
included hospital-based observational studies reporting clinical laboratory parameters of
confirmed cases of COVID-19 and excluded studies having large proportions (>10%) of chil-
dren and pregnant women. Two authors independently carried out screening of articles,
data extraction and quality assessment. Meta-analyses were done using random effects
model. Meta-median difference (MMD) and 95% confidence interval (CI) was calculated for
each laboratory parameter. Forty-five studies in 6 countries were included. Compared to
non-severe COVID-19 cases, severe or critical COVID-19 was characterised by higher neu-
trophil count (MMD: 1.23 [95% CI: 0.58 to 1.88] ×109 cells/L), and lower lymphocyte, CD4
and CD8 T cell counts with MMD (95% CI) of -0.39 (-0.47, -0.31) ×109 cells/L, -204.9
(-302.6, -107.1) cells/μl and -123.6 (-170.6, -76.6) cells/μl, respectively. Other notable
results were observed for C-reactive protein (MMD: 36.97 [95% CI: 27.58, 46.35] mg/L),
interleukin-6 (MMD: 17.37 [95% CI: 4.74, 30.00] pg/ml), Troponin I (MMD: 0.01 [0.00, 0.02]
ng/ml), and D-dimer (MMD: 0.65 [0.45, 0.85] mg/ml).
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Conclusions
Relative to non-severe COVID-19, severe or critical COVID-19 is characterised by
increased markers of innate immune response, decreased markers of adaptive immune
response, and increased markers of tissue damage and major organ failure. These markers
could be used to recognise severe or critical disease and to monitor clinical course of
COVID-19.
Introduction
Coronavirus disease 2019 (COVID-19) is an emerging zoonosis caused by Severe Acute Respi-
ratory Syndrome Coronavirus 2 (SARS-CoV-2) [1, 2]. Phylogenetically, SARS-CoV-2 suffi-
ciently differs from other zoonotic coronaviruses, such as Severe Acute Respiratory Syndrome
Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
introduced to humans in the past two decades [1, 3]. Disease resulting from infection with
SARS-CoV-2 was first reported in Wuhan, China in December 2019, and the virus rapidly
spread to other regions of the world thereafter [4, 5]. Given the scale of the outbreak, COVID-
19 was declared a pandemic on March 12 2020 by the World Health Organization [6]. As of
April 19, 2020, there have been 2,394,291 confirmed cases in 185 countries/regions and
164,938 COVID-related deaths [7].
Clinical features of infection with SARS-CoV-2 vary widely and have been classified as
mild, severe or critical, with some persons remaining asymptomatic [8, 9]. Majority of SARS--
CoV-2 infected persons display mild symptoms similar to a viral upper respiratory tract infec-
tion such as dry cough, fever, sore throat, nasal congestion, and muscle pain [8–10]. Severe
COVID-19 is characterised by features of severe pneumonia such as dyspnoea, respiratory fre-
quency�30 breaths per minute and blood oxygen saturation�93%, while critical COVID-19
is characterised by respiratory failure, septic shock, and/or multiple organ failure [8, 9]. Severe
or critical COVID-19 is highly associated with mortality [11]. In a single-centre observational
study of critical COVID-19 patients, up to 61% of critical COVID-19 patients and 94% of criti-
cal COVID-19 patients requiring mechanical ventilation died within 28 days of admission into
the intensive care unit [12].
Currently, there is no approved cure for infection with SARS-CoV-2 and an effective vac-
cine is not yet available. Approximately 18% of diagnosed COVID-19 cases have severe or crit-
ical disease, and about 5% of diagnosed COVID-19 require intensive care management with
or without mechanical ventilation [8, 13]. Consequently, there is substantial pressure on
healthcare systems worldwide, particularly on intensive care units. As healthcare systems
become further stretched by the increasing numbers of cases, identifying clinical laboratory
parameters associated with severe and critical cases is crucial in helping clinicians triage
patients appropriately and optimize use of the limited healthcare resources. Furthermore, as
more clinical trials are being launched to test possible treatments for COVID-19, laboratory
parameters associated with COVID-19 severity can aid in monitoring the clinical evolution of
cases on trial drugs and serve as composite or secondary outcomes for these trials.
To date, changes in several clinical laboratory parameters have been linked to COVID-19
severity [4, 13–16]. However, it is not clear if these changes are observed consistently across
studies. With these considerations in mind, the objective of this systematic review and meta-
analysis was to investigate which clinical laboratory parameters may be associated with severe
or critical COVID-19 disease.
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Methods
Protocol and registration
We registered our study protocol with the International Prospective Register of Systematic
Reviews (PROSPERO); registration number CRD42020176651 [17]. This review and meta-
analysis was conducted and has been reported according to The Preferred Reporting Items for
Systematic Reviews and Meta- Analyses (PRISMA) statement and Meta-analysis of Observa-
tional Studies in Epidemiology (MOOSE) guidelines [18, 19].
Eligibility criteria
This review and meta-analysis included observational studies reporting clinical laboratory
parameters among patients with confirmed COVID-19. Cases were diagnosed using guidelines
by either the World Health Organization or the China National Commission for Health [20,
21].
The exposure of interest of this review was severe or critical COVID-19 and the comparator
was non-severe COVID-19. According to the criteria defined by China National Health Com-
mission, severe COVID-19 is characterised by dyspnoea,�30 breaths/minute, blood oxygen
saturation�93%, arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/
FiO2) ratio <300, and/or lung infiltrates >50% within 24–48 hours; and critical COVID-19 is
characterised by respiratory failure, septic shock, and/or multiple organ failure [22]. Non-
severe COVID-19 is defined by no or mild pneumonia [22]. We also considered COVID-19
cases requiring oxygen therapy, and COVID-19 cases admitted to intensive care units as severe
or critical cases.
The outcomes of interest were clinical laboratory parameters. These included hematologic
indices (White blood cells, Neutrophils, Lymphocytes, Monocytes, Platelets, Haemoglobin,
CD3, CD4, CD8), biochemical indices (Total bilirubin, Alanine aminotransferase, Aspartate
aminotransferase, Total protein, Albumin, Globulin, Prealbumin, Urea, Creatinine, Glucose,
Creatine kinase muscle-brain, Troponin I, Cholinesterase, Cystatin C, Lactate dehydrogenase,
α-hydroxybutyric dehydrogenase), infection/inflammation-related indices (C-reactive protein
[high sensitivity and standard], Interleukin-6, Erythrocyte sedimentation rate, Procalcitonin,
Serum ferritin), coagulation indices (Prothrombin time, Activated partial thromboplastin, D-
dimer) and electrolytes (Sodium, Potassium, Calcium, Chloride).
We included only hospital-based studies and excluded reviews, opinion articles, and studies
that did not report clinical laboratory parameters stratified by COVID-19 disease severity.
Also, as children and pregnant women have different cut-off values for most clinical laboratory
parameters compared to general adults, we excluded studies that examined populations with
large proportions of children under 11 years of age and pregnant women to reduce clinical het-
erogeneity. We considered studies that included children, pregnant women along with the
general adult population as eligible only if the proportion of children or pregnant women con-
stituted less than 10%.
Search strategy
We conducted a systematic search of Ovid MEDLINE, Ovid Embase, Clarivate Analytics Web
of Science Core Collection, EBSCO CINAHL and Google Scholar databases from 2019
through April 18, 2020. The search strategy used both controlled vocabulary and free text
words relevant to COVID-19 and clinical laboratory parameters (see search strategy in S1 Text
in S1 File). We also reviewed bibliographies of eligible studies, relevant systematic reviews to
identify additional papers that were missed by the electronic search. Further, we performed a
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manual search of the medRxiv pre-print server to identify latest relevant studies that might still
be undergoing peer-review. The search was limited to the years 2019–2020 and there was no
limitation regarding language of publication.
Study selection
Following deduplication of records retrieved during the systematic search, we exported
retained articles into Covidence review manager to facilitate the screening of titles and
abstracts, which was followed by a full text review to determine eligibility [23].
Two authors (JM and PP) independently carried out title and abstract screening and full
text evaluation of all articles using the eligibility criteria listed in the previous section. The dis-
crepancies in study selection were resolved through adjudication by a third author (KM). To
avoid including data on the same patient populations more than once in the meta-analysis, we
matched studies based on the location of the study (hospital, town) and the period over which
data was collected. For two or more studies conducted at the same location over the same or
overlapping periods, we included only the largest study, unless one of the smaller studies pre-
sented relevant information not included in the larger study.
Data extraction and data items
Two authors (JM and PP) independently extracted, verified and summarized data from each
study included in the meta-analysis. The information extracted from the selected studies
included: study author(s), study sponsors, date of publication, study period, study location,
study design, sample size, sample characteristics (age, gender, comorbidities), exposure char-
acteristics (study definition of severity of COVID-19, timing of classification of disease severity
[on admission or otherwise], number of cases with non-severe COVID-19, number of cases
with severe or critical COVID-19), timing of blood sample collection (on admission or other-
wise), clinical laboratory parameters stratified by COVID-19 severity, mean (standard devia-
tion [SD]) and/or median (interquartile range [IQR] or minimum-maximum [total] range) of
clinical laboratory parameters when reported on continuous scales, and numbers (percent-
ages) of cases above and below cut-off values when reported on categorical scales. Discrepan-
cies in collected data were resolved by re-checking the primary studies until consensus was
reached. For the studies which had unclear severity classification, the authors were contacted
to seek additional clarification. Studies in the Chinese language were translated into English
language by a Chinese native speaker. The extracted data were exported into R programming
software.
Quality assessment
Two authors (AK and MN) independently carried out quality assessment of each article using
National Institutes of Health (NIH) study quality assessment tools for observational cohort
and cross-sectional studies, and for case series studies [24]. These tools were used to evaluate
the risk of bias and to assess the overall validity of reported results. Each study was assessed
using all elements of the relevant tool, and an overall judgement was made by considering the
responses to the various elements. An overall rating of poor quality translates to a high risk of
bias, and an overall rating of good quality translates to a low risk of bias [24]. The final decision
for each study was made through professional judgement and by consensus among the
authors. We evaluated the impact of studies with a high risk of bias by doing sensitivity analysis
using the Leave-One-Out method [25].
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Summary measures and data synthesis
Where clinical laboratory parameters were measured on a continuous scale, we pooled median
differences from each study using the quantile estimation method [26]. The result of this anal-
ysis was expressed as a meta-median difference (MMD) accompanied by a corresponding 95%
confidence interval (CI). We preferred median differences over mean differences because clin-
ical laboratory indices are usually skewed, and mean values could be influenced by outlier val-
ues, particularly in small samples. We performed a sensitivity analysis by pooling mean
differences from each study using inverse variance weighting. Where the studies reported only
median (IQR or total range) values, we computed mean (SD) using methods previously
described [27, 28].
Where clinical laboratory parameters were measured on a categorical scale, we computed
prevalence ratios for each study using counts of events in the exposure and comparator group
and calculated meta-prevalence ratios (MPR) and the 95% CIs using the Mantel-Haenszel
method.
Meta-analysis was conducted using random effect models. We assessed clinical heterogene-
ity (age distribution, comorbidities criteria of severity) and study methodological heterogene-
ity (timing of blood sample collection) and considered the potential impact of these factors on
the meta-analysis results. We assessed statistical heterogeneity using Cochran’s Q test and cal-
culated the I2 statistic, which was interpreted using cut-offs of 25%, 50%, and 75% for low,
moderate, and substantial heterogeneity, respectively. We performed influence analysis using
the Leave-One-Out-method to identify studies that have a high influence on our results [25].
Additional sensitivity analyses were performed by excluding ‘outlier’ studies. A study-specific
estimate was considered an outlier if its confidence interval did not overlap with the confi-
dence interval of the meta-estimate [25].
To detect possible publication bias, funnel plots were constructed for the 4 laboratory
parameters with the highest number of individual studies. Egger’s test was carried out to assess
statistical symmetry of the plots.
Statistical analyses were done using R programming software and in the ’meta’, ’metafor’,
’dmetar’ and ’metadian’ packages [29].
Results
Study selection
We identified 3,779 studies through database searching and from other sources (Fig 1). After
removing duplicates, 1722 unique records were screened, and of those, 1398 were removed
after title and abstract review. Additional 257 records were excluded due to lack of COVID-19
severity classification, lack of laboratory parameter records or ineligible study design. Of the
67 remaining studies, another 22 were excluded because they used data from the same loca-
tions or covered overlapping periods (see S2 Text in S1 File). A total of 45 studies were retained
for meta-analyses.
Study characteristics
The characteristics of included studies are detailed in Table 1 and S3 Table in S1 File. All stud-
ies included in the meta-analyses were observational and hospital based. The majority of 45
studies (87%) were from China; and of those, 14 were from Wuhan and 25 from other loca-
tions in China. Two studies were from the USA, and the remaining 4 studies were from
France, Germany, Japan and Singapore. All studies were published in 2020 and the data collec-
tion covered the period from December 25th, 2019 to April 2nd, 2020. The median population
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size of the included studies was 97 (IQR: 49–221). Data were collected retrospectively in all but
one study [30]. COVID-19 severity was classified using China National Health Commission
guidelines (20 studies), WHO guidelines (4 studies), American Thoracic Society guidelines (2
studies), Berlin criteria (1 study), Complementary and Natural Healthcare council (1 study),
or unspecified guidelines (17 studies). Studies classified severity on admission (22 studies,
49%), on the ward (11 studies, 24%), or during unspecified periods (12 studies, 27%). Clinical
laboratory tests were done on admission (33 studies, 73%), post-admission (5 studies, 11%)
and at unspecified periods (7 studies, 16%). The highest number of laboratory parameters
Fig 1. PRISMA flowchart of study selection.
https://doi.org/10.1371/journal.pone.0239802.g001
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Table 1. Characteristics of included studies.
Study Study characteristics Patient characteristics aRisk of
Bias
eCai et al. [44] Hospital(s): Third people’s Hospital of Shenzhen Number of non-severe COVID-19 cases: 240 Low
Number of severe/critical COVID-19 cases: 58
bAge: 47 (33–61) years, Males: 149/298 (50.0%), Hypertension:
38/298 (12.8%), Diabetes: 19/298 (6.4%), Cancer: 4/298 (1.4%)
Location(s): Shenzhen, China
Study period: 11 Jan 2020–6 Feb 2020
Sample size: 298
Cao Min et al.
[45]
Hospital(s): Shanghai Public Health Clinical Centre Number of non-severe COVID-19 cases: 179 Low
Number of severe/critical COVID-19 cases: 19
dAge: 50.1 (16.3) years, Males: 101/198 (51.0%), Hypertension:
42/198 (21.2%), Diabetes: 15/198 (7.6%), Cancer: 4/198 (2.0%)
Location(s): Shanghai, China
Study period: x Jan 2020—x Feb 2020
Sample size: 198
Cao Weiliang
et al. [46]
Hospital(s): Xiangyang No.1 Hospital Number of non-severe COVID-19 cases: 107 High
Location(s): Xiangyang, China Number of severe/critical COVID-19 cases: 21
Study period: 1 Jan 2020–16 Feb 2020 Age: >65 years = 24 (18.8%), Males: 60/128 (46.9%),
Hypertension: NR, Diabetes: NR, Cancer: NRSample size: 128
Chen Dong
et al. [47]
Hospital(s): Wenzhou Central Hospital, 6th People’s Hospital of
Wenzhou
Number of moderate/non-severe COVID-19 cases: 135 Low
Number of severe/critical COVID-19 cases: 40
Location(s): Wenzhou, Zhejiang Province, China bAge: 46 (34–54) years, Males: 83/175 (47.4%), Hypertension:
28/175 (16.0%), Diabetes: 12/175 (6.8%), Cancer: NRStudy period: 11 Jan 2020–15 Feb 2020
Sample size: 175
fChen Guang
et al. [48]
Hospital(s): Tongji Hospital Number of non-severe COVID-19 cases: 10 Medium
Location(s): Wuhan, China Number of severe/critical COVID-19 cases: 11
Study period: late Dec 2019–27 Jan 2020 bAge: 56 (50–65) years, Males: 17/21 (81.0%), Hypertension: 5/
21 (23.8%), Diabetes: 3/21 (14.3%), Cancer: NRSample size: 21
Chen Meizhu
et al. [49]
Hospital(s): Fifth Affiliated Hospital of Sun Yat-sen University Number of moderate/non-severe COVID-19 cases: 71 Low
Number of severe/critical COVID-19 cases: 26
Location(s): Zhuhai, China dAge: 47.5(15–80) years, Males: 42/97 (43.3%), Hypertension:
16/97 (16.5%), Diabetes: 6/97 (6.2%), Cancer: 6/97 (6.2%)Study period: 17 Jan 2020–10 March 2020
Sample size: 97
Dai et al. [32] Hospital(s): Hospitals in Hunan Province Number of non-severe COVID-19 cases: 77 High
Location(s): Hunan province Number of severe/critical COVID-19 cases: 841
cAge: 44.73 (16.0) years, Males: 479/918 (52.18%), Hypertension:
NR, Diabetes: NR, Cancer: NR
Study period: 21 Jan 2020 to 13 Feb 2020
Sample size: 918
Fang et al. [50] Hospital(s): Anhui Provincial Hospital Number of non-severe COVID-19 cases: 55 Low
Location(s): Anhui province Number of severe/critical COVID-19 cases: 24
Study period: 22 Jan 2020–18 Feb 2020 cAge: 45.1 (16.6) years, Males: 45/79 (57.0%)
Sample size: 79 Hypertension: 16/79 (20.3%), Diabetes: 8/79 (14.5%), Cancer: 1/
79 (1.3%)
Gong et al. [51] Hospital(s): Guangzhou Eighth People’s Hospital, Zhongnan
Hospital of Wuhan University and the Third Affiliated Hospital of
Sun Yat-sen University, but 189 used in the analysis come only from
Guangzhou Eighth People’s Hospital
Number of non-severe COVID-19 cases: 161 Low
Number of severe/critical COVID-19 cases: 28
bAge: 49.0 (35.0–63.0) years
Males: 88/189 (46.6%)
Proportion with at least one severe disease (Hypertension,
Diabetes, Cardiovascular disease, Chronic Respiratory Disease,
Tuberculosis): 55/189 (29.1%)
Location(s): Ghaungzhou and Wuhan, but 189 only from
Ghaungzhou
Study period: 20 Jan 2020–2 Mar 2020
Sample size: 189
(Continued)
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Table 1. (Continued)
Study Study characteristics Patient characteristics aRisk of
Bias
Goyal et al. [52] Hospital(s): New York-Presbyterian Hospital’s Weill Cornell
Medical Center and Lower Manhattan Hospitals
Number of non-severe COVID-19 cases: 263 Low
Number of severe/critical COVID-19 cases: 130
bAge: 62.2 (48.6–73.7) years, Males: 238/393 (60.6%),
Hypertension: 197/393 (50.1%), Diabetes: 99/393 (25.2%),
Cancer: 23/393 (5.9%).
Location(s): New York, USA
Study period: 5 March 2020–27 March 2020
Sample size: 393
gGuan et al.
[13]
Hospital(s): 552 sites across china with largest number from Wuhan
Jinyintan Hospital (132)
Number of non-severe COVID-19 cases: 926 Medium
Number of severe/critical COVID-19 cases: 173
bAge: 47 (35–58) years
Males: 637/1096 (58.1%)
Location(s): Multiple cities, China Hypertension: 165/1099 (15%), Diabetes: 81/1099 (7.4%)
Study period: 11 Dec 2020–29 Jan 2020 Cancer: 10/1099 (0.9%)
Sample size: 1099
hHan et al. [53] Hospital(s): Renmin Hospital of Wuhan University Number of non-severe COVID-19 cases: 23 Low
Number of severe/critical COVID-19 cases: 24
bAge: 64.91 (31–87) years, Males: 26/47 (55.31%), Hypertension:
18/47 (38.30%), Diabetes: 7/47 (14.89%), Cancer: NR
Location(s): Wuhan, China
Study period: 1 Feb 2020–18 Feb 2020
Sample size: 47
Herold et al.
[14]
Hospital(s): University Hospital, Ludwig Maximilian University of
Munich
Number of non-severe COVID-19 cases: 27 Low
Number of severe/critical COVID-19 cases: 13
Location(s): Munich, Germany bAge: 57 (19–81) years, Males: 29/40 (72%), Hypertension: 19/36
(53%), Diabetes: 3/37 (8%), Cancer: NRStudy period: 29 Feb 2020–27 Mar 2020
Sample size: 40
Hu et al. [54] Hospital(s): Tianyou Hospital Number of non-severe COVID-19 cases: 151 Medium
Number of severe/critical COVID-19 cases: 172
Location(s): Wuhan dAge: 61 (23–91) years, Males: 166/323 (51.4%), Hypertension:
105/323 (32.5%), Diabetes: 47/323 (14.6%), Cancer: 5/323 (1.5%)Study period: 8 Jan 2020–20 Feb 2020
Sample size: 323
Lescure et al.
[55]
Hospital(s): Bichat-Claude Bernard University Hospital and
Pellegrin University Hospital
Number of non-severe COVID-19 cases: 2 Low
Number of severe/critical COVID-19 cases: 3
bAge: 46 (30–80) years
Males: 3/5 (60.0%), Hypertension: 1/5 (20%)
Location(s): Paris and Bordeaux, France Diabetes: 0 (0%), Cancer: 1/5 (20%)
Study period: 23 Jan 2020–14 Feb 2020
Sample size: 5
Liu Chuan et al.
[56]
Hospital(s): Lanzhou University First Hospital, Shenyang Sixth
People’s Hospital, Ankang Central Hospital, Lishui Central Hospital,
Zhenjiang Third People’s Hospital, Baoding People’s Hospital,
Linxiazhou People’s Hospital
Number of non-severe COVID-19 cases: 28 High
Number of severe/critical COVID-19 cases: 4
bAge: 38.5 (26.25–45.75) years
Males: 20/32 (62.5%)
Hypertension: 1/32 (3.1%)
Diabetes: NR
Cancer: 2/32 (6.25%)Location(s): Lanzhou, Shanghai, Ankang, Lishui, Zhenjiang,
Baoding and Linxia. China
Study period: 23 Jan 2020–8 Feb 2020
Sample size: 32
(Continued)
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Table 1. (Continued)
Study Study characteristics Patient characteristics aRisk of
Bias
Liu Jingyuan
et al. [30]
Hospital(s): Beijing Ditan Hospital Number of non-severe COVID-19 cases: 44 Low
Location(s): Beijing, China Number of severe/critical COVID-19 cases: 17
Study period: 13 Jan 2020–31 Jan 2020 dAge: [non-severe: 41.00 (1.0–76.0) years, severe: 56.00 (34.0–
73.0)] yearsSample size: 61
Males: 31/61 (50.8%), Hypertension: 12/61 (19.7%), Diabetes: 5/
61 (8.2%), Cancer: NR
Liu Min et al.
[57]
Hospital(s): Affiliated hospital of Jianghan University Number of non-severe COVID-19 cases: 26 Medium
Number of severe/critical COVID-19 cases: 4
Location(s): Wuhan, China cAge: 35.0 (8) years
Study period: Jan 2020 Males: 10/30 (33.3%), Hypertension: NR, Diabetes: NR, Cancer:
NRSample size: 30
iLiu Tao et al.
[58]
Hospital(s): Union Hospital Number of non-severe COVID-19 cases: 11 Medium
Location(s): Wuhan, China Number of severe/critical COVID-19 cases: 69
bAge: 53.00 (26.0–86.0) years, Males: 34/80 (42.50%),
Hypertension: 14/80 (17.50%), Diabetes: 11/80 (13.75%),
Cancer: 7/80 (8.75%)
Study period: 21 Jan 2020–16 Feb 2020
Sample size: 80
jLiu Yanli et al.
[59]
Hospital(s): Central Hospital of Wuhan Number of non-severe COVID-19 cases: 56 Medium
Location(s): Wuhan, China Number of severe/critical COVID-19 cases: 53
Study period: 2 Jan 2020–1 Feb 2020 bAge: 55.0 (43.0–66.0) years
Sample size: 109 Males: 59/109 (54.1%)
Hypertension: 37/109 (33.9%)
Diabetes: 12/109 (11.0%)
Cancer: NR
Liu Min et al.
[57]
Hospital(s): Affiliated hospital of Jianghan University Number of non-severe COVID-19 cases: 26 Medium
Number of severe/critical COVID-19 cases: 4
Location(s): Wuhan, China cAge: 35.0 (8) years
Study period: Jan 2020 Males: 10/30 (33.3%), Hypertension: NR, Diabetes: NR, Cancer:
NRSample size: 30
hLuo et al. [60] Hospital(s): Renmin Hospital of Wuhan University Number of non-severe COVID-19 cases: 141 Low
Number of severe/critical COVID-19 cases: 157
bAge: 57.0 (40.0–69.0) years
Location(s): Wuhan, China Males: 150/298 (50.3%), Hypertension: 86/298 (28.9%),
Diabetes: 45/298 (15.1%)Study period: 30 Jan 2020–20 Feb 2020
Sample size: 298 Cancer: NR
Petrilli et al.
[61]
Hospital(s): NYU Langone Health Number of non-severe COVID-19 cases: 932 Low
Location(s): New York, USA Number of severe/critical COVID-19 cases: 650
Study period: 1 March 2020–2 April 2020 bAge: [non-severe: 58.0(46–71.0) years, severe: 67.0 (56–77.0)
years]
Sample size: 1582 Males: [non-severe: 560/932 (60.1%), severe: 442/650 (68%)]
Hypertension: [non-severe: 320/932 (34.3%), severe: 257/650
(39.5%)]
Diabetes: [non-severe: 213/932 (22.9%), severe: 176/650 (27.1%)]
Cancer: [non-severe: 54/932 (5.8%), severe: 56/650 (8.6%)]
(Continued)
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Table 1. (Continued)
Study Study characteristics Patient characteristics aRisk of
Bias
Qian et al. [62] Hospital(s): Five hospitals in Zhejiang province Number of non-severe COVID-19 cases: 82 Medium
Number of severe/critical COVID-19 cases: 9
Location(s): Zhejiang province, China bAge: 50.0 (36.50–57.0) years
Study period: 20 Jan 2020–11 Feb 2020 Males: 37/91 (40.66%)
Sample size: 91 Hypertension: 15/91 (16.48%)
Diabetes: 8/91 (8.79%), Cancer: NR
fQin et al. [63] Hospital(s): Tongji Hospital Number of non-severe COVID-19 cases: 166 Low
Location(s): Wuhan, China Number of severe/critical COVID-19 cases: 286
bAge: 58.0 (47.0–67.0) years
Study period: 10 Jan 2020–12 Feb 2020 Males: 235/452 (52%), Hypertension: 135/452 (29.50%),
Diabetes: 75/452 (16.4%), Cancer: 14/452 (3.1%)Sample size: 452
Qu et al. [64] Hospital(s): Huizhou Municipal Central Hospital Number of non-severe COVID-19 cases: 27 Low
Number of severe/critical COVID-19 cases: 3
bAge: 50.5 (36.0–65.0) years, Males: 16/30 (53.3%)
Location(s): Huizhou, China Hypertension: NR, Diabetes: NR, Cancer: NR
Study period: Jan 2020—Feb 2020
Sample size: 30
Tabata et al.
[16]
Hospital(s): Self-Defense Forces Central Hospital Number of non-severe COVID-19 cases: 78 Low
Number of severe/critical COVID-19 cases: 28
Location(s): Tokyo, Japan bAge: 68.0 (46.75–75.0) years
Study period: 11 Feb 2020–25 Feb 2020 Males: 47/104 (45.2%), Hypertension: NR, Diabetes: 7/104
(7.7%)
Sample size: 104 Cancer: 4/104 (3.8%)
Wan et al. [65] Hospital(s): Chongqing University Three Gorges Hospital Number of non-severe COVID-19 cases: 95 Low
Number of severe/critical COVID-19 cases: 40
bAge: 47.0 (36.0–55.0) years, Males: 72/135 (53.3%),
Hypertension: 13/135 (9.6%), Diabetes: 12/135 (8.9%)
Location(s): Chongqing, China
Study period: 23 Jan 2020–8 Feb 2020 Cancer: 4/135 (3.0%)
Sample size: 135
iWang et al.
[66]
Hospital(s): Union Hospital Number of non-severe COVID-19 cases: 55 Low
Location(s): Wuhan, China Number of severe/critical COVID-19 cases: 14
Study period: 16 Jan 2020–29 Jan 2020 bAge: 42.0 (35.0–62.0) years
Sample size: 69 Males: 32/69 (46%), Hypertension: 9/69 (13%), Diabetes: 7/69
(10%)
Cancer: 4/69 (6%)
Wu Chaomin
et al. [67]
Hospital(s): Jinyintan Hospital Number of non-severe COVID-19 cases: 117 Low
Location(s): Wuhan, China Number of severe/critical COVID-19 cases: 84
Study period: 25 Dec 2019–26 Jan 2020 bAge: 51.0 (43.0–60.0) years
Sample size: 201 Males: 128/201 (63.7%), Hypertension: 39/201 (19.4%),
Diabetes: 22/201 (10.9%), Cancer: 1/201 (0.5%)
(Continued)
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Table 1. (Continued)
Study Study characteristics Patient characteristics aRisk of
Bias
Wu Jian et al.
[68]
Hospital(s): First People’s Hospital of Yancheng City, the Second
People’s Hospital of Fuyang City, the Second People’s Hospital of
Yancheng City, and the Fifth People’s Hospital of Wuxi.
Number of non-severe COVID-19 cases: 197 Medium
Number of severe/critical COVID-19 cases: 83
cAge: 43.12 (19.02) years
Males: 151/280 (53.93%)
CVD and CeVD: 57/280 (20.36%)
ESD: 34/280 (12.14%)
Location(s): Yancheng, Fuyang, Wuxi, Jiangsu and Anhui
provinces, China
Cancer: 5/280 (1.79%)
Study period: 20 Jan 2020–19 Feb 2020
Sample size: 280
Xiang Jialin
et al. [69]
Hospital(s): The First Affiliated Hospital of Zunyi Medical
University and The Fourth People’s Hospital of Zunyi city
Number of non-severe COVID-19 cases: 20 Medium
Number of severe/critical COVID-19 cases: 8
cAge: [non-severe: 41.0 (19) years, severe: 66.0 (22) years]
Males: 15/28 (53.57%)
Location(s): Zunyi, Guizhou Province, China Hypertension: 5/28 (17.86%)
Diabetes: 4/28 (14.29%)
Cancer: NRStudy period: 29 Jan 2020–21 Feb 2020
Sample size: 28
Xiang Tianxin
et al. [70]
Hospital(s): The First Affiliated Hospital of Nanchang University Number of non-severe COVID-19 cases: 40 Low
Number of severe/critical COVID-19 cases: 9
bAge: 42.9 (18–78) years, Males: 33/49 (67.3%), Hypertension: 6/
49 (12.24%), Diabetes: 2/49 (4.1%), Cancer: NR
Location(s): Jiangxi Province, China
Study period: 21 Jan 2020–27 Jan 2020
Sample size: 49
kXu et al. [71] Hospital(s): Zhongnan Hospital of Wuhan University, Chinese PLA
General Hospital, Peking Union Medical College Hospital, and
affiliated hospitals of Shanghai University of Medicine & Health
Sciences
Number of non-severe COVID-19 cases: 44 Low
Number of severe/critical COVID-19 cases: 25
bAge: 57 (43–69) years
Males: 35/69 (50.7%)
Hypertension, Diabetes, Cancer: Patients with comorbidities are
excluded
Location(s): Wuhan, Shanghai, Beijing, China
Study period: 7 Feb 2020–28 Feb 2020
Sample size: 69
Yan et al. [72] Hospital(s): Hospitals in Hainan Number of non-severe COVID-19 cases: 132 Medium
Location(s): Hainan, China Number of severe/critical COVID-19 cases: 36
Study period: 22 Jan 2020–13 Mar 2020 bAge: 51 (36–62) years, Males: 81/168 (48.2%), Hypertension:
24/168 (14.3%)Sample size: 168
Diabetes: 12/168 (17.1%), Cancer: 2/168 (1.2%)
lYuan et al. [73] Hospital(s): Chongqing Public Health Center for Medical
Treatment
Number of non-severe COVID-19 cases: 192 Low
Number of severe/critical COVID-19 cases: 31
Location(s): Chongqing, China cAge: 46.5 (16.1) years
Study period: 24 Jan 2020–23 Feb 2020 Males: 105/223 (47.09%), Hypertension: 25/223 (11.21%)
Sample size: 223 Diabetes: 18/223 (8.07%)
Cancer: NR
(Continued)
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Table 1. (Continued)
Study Study characteristics Patient characteristics aRisk of
Bias
Young et al.
[74]
Hospital(s): National Centre for Infectious Diseases, Singapore
General Hospital, Changi General Hospital, Sengkang General
Hospital
Number of non-severe COVID-19 cases: 12 Medium
Number of severe/critical COVID-19 cases: 6
dAge: 47 (31–73) years, Males: 9/18 (50%), Hypertension: 4/18
(22.22%)
Diabetes: 1/18 (5.56%), Cancer: NRLocation(s): Singapore
Study period: 23 Jan—3 Feb
Sample size: 18
eZeng et al. [75] Hospital(s): Shenzhen Third People’s hospital Number of non-severe COVID-19 cases: 262 Low
Number of severe/critical COVID-19 cases: 76
Location(s): Shenzhen, China cAge: 49.0 (14.5) years
Study period: 11 Jan 2020–28 Feb 2020 Males: 162/338 (47.9%), Hypertension: 51/338 (15.1%),
Diabetes: 25/338 (7.4%), Cancer: 2/338 (0.6%)Sample size: 338
Zhang Gemin
et al. [76]
Hospital(s): Xinzhou District People’s Hospital Number of non-severe COVID-19 cases: 63 Medium
Number of severe/critical COVID-19 cases: 32
dAge: 49.0 (39.0–58.0) years
Location(s): Xinzhou District, Wuhan, China Males: 53/95 (55.8%), Hypertension: NR, Diabetes: NR
Cancer: NRStudy period: 16 Jan 2020–25 Feb 2020
Sample size: 95
kZhang Guqin
et al. [77]
Hospital(s): Zhongnan Hospital of Wuhan University Number of non-severe COVID-19 cases: 166 Low
Number of severe/critical COVID-19 cases: 55
bAge: 55.0 (39.0–66.5) years
Location(s): Wuhan, China Males: 108/221 (48.9%), Hypertension: 54/221 (24.4%),
Diabetes: 22/221 (10%), Cancer: 9/221 (4.1%)Study period: 2 Jan 2020–10 Feb 2020
Sample size: 221
lZhang
Huizheng et al.
[78]
Hospital(s): Chongqing Public Health Medical Center Number of non-severe COVID-19 cases: 29 Medium
Number of severe/critical COVID-19 cases: 14
Location(s): Chongqing, China cAge: [non-severe: 44.34 (15.84) years, severe: 61.70 (9.22) years]
Study period: 11 Feb 2020–28 Feb 2020 Males: 22/43 (51.2%), Hypertension: 4/43 (9.3%), Diabetes: 6/43
(14%)Sample size: 43
Cancer: NR
Zhang Jin-jin
et al. [79]
Hospital(s): No. 7 Hospital of Wuhan Number of non-severe COVID-19 cases: 82 Medium
Location(s): Wuhan, China Number of severe/critical COVID-19 cases: 58
Study period: 15 Jan 2020–3 Feb 2020 bAge: 57.00 (25.00–87) years
Males: 71/140 (50.7%), Hypertension: 42/140 (30%), Diabetes:
17/140 (12.1%), Cancer: NR
Sample size: 140
Zhao et al. [80] Hospital(s): Beijing YouAn Hospital Number of non-severe COVID-19 cases: 57 Low
Location(s): Beijing, China Number of severe/critical COVID-19 cases: 20
Study period: 21 Jan 2020–8 Feb 2020 cAge: 52.0 (20.0) years
Sample size: 77 Males: 34/77 (44.2%), Hypertension: 16/77 (20.8%), Diabetes: 6/
77 (7.8%), Cancer: 4/77 (5.2%)
(Continued)
PLOS ONE Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19)
PLOS ONE | https://doi.org/10.1371/journal.pone.0239802 October 1, 2020 12 / 25
reported in a single study was 30 [31] and the lowest number of laboratory parameters
reported in a single study was 2 [32].
The median (or mean) age of patients in the included studies ranged from 35 years to 67
years, and the proportion of male patients ranged from 30% to 81%. Patients in the included
studies had varying proportions of comorbidities such as hypertension, diabetes and cancer as
detailed in Table 1 (and S3 Table in S1 File).
Synthesis of results
Results of meta-analyses are reported in Table 2, and Forest plots and Leave-One-Out analysis
are displayed in S4 Fig in S1 File.
As pertains to haematological parameters, the majority of studies reported higher white cell
count and higher neutrophil count in severe or critical COVID-19 patients relative to non-
severe COVID-19 patients. Median difference in individual studies ranged from -1.6 to 7.3
(×109 cells/L) for white cell count and from -1.0 to 5.2 (×109 cells/L) for neutrophil count. The
MMD estimates (109 cells/L) were 0.87 (95% CI: 0.35 to 1.40; I2: 80.5%) for white cell count
and 1.23 (95% CI 0.58 to 1.88; I2: 90%) for neutrophil count. When the results were expressed
in terms of ratio measures, patients with severe or critical COVID-19 had significantly higher
Table 1. (Continued)
Study Study characteristics Patient characteristics aRisk of
Bias
Zheng et al.
[37]
Hospital(s): The First Affiliated Hospital of Anhui Medical
University and Fuyang second people’s Hospital
Number of non-severe COVID-19 cases: 55 Medium
Number of severe/critical COVID-19 cases: 13
dAge: 47.13 (11–84) years
Males: 36/68 (52.9%)
Location(s): Hefei, Fuyang, China Hypertension: NR
Diabetes: NR
Study period: NR Cancer: NR
Sample size: 68
jZhou et al. [81] Hospital(s): Central Hospital Wuhan Number of non-severe COVID-19 cases: 260 Low
Number of severe/critical COVID-19 cases: 117
Location(s): Wuhan, China cAge: [non-severe: 48.35 (16.17) years, severe: 65.63 (14.03) years]
Study period: 1 Jan 2020–28 Feb 2020 Males: [non-severe: 102/260(39.23%), severe: 68/117 (58.12%)]
Sample size: 377 Hypertension: [non-severe: 63/260(24.23%), severe: 70/117
(59.83%)]
Diabetes: [non-severe: 42/260(16.15%), severe: 42/117 (35.9%)]
Cancer: NR
NR: Not Reported.
Age is reported as
cmean (SD) /median(IQR)b /median (range)d.
aOverall Risk of Bias by professional judgement and consensus by authors. See S5 Table in S1 File for detailed judgement.
eMatched to Shenzhen Third People’s hospital; Parameters extracted from Cai et al. were only those not reported by Zeng et al.
fMatched to Tongji hospital; Parameters extracted from Chen G et al. were only those not reported by Qin et al.
gMulticenter study; possibly overlapping with Wu Chaomin et al. (Jinyintan Hospital).
hMatched to Renmin Hospital of Wuhan University; Parameters extracted from Han et al. were only those not reported by Luo et al.
iMatched to Union Hospital; Parameters extracted from Wang et al. were only those not reported by Liu Tao et al.
jMatched to Central Hospital Wuhan; Parameters extracted from Zhou et al. were only those not reported by Liu Yanli et al.
kMatched to Zhongnan Hospital of Wuhan, however data collected over different periods.
lMatched to Chongqing Public Health Medical Center; Parameters extracted from Zhang et al. were only those not reported by Yuan et al.
https://doi.org/10.1371/journal.pone.0239802.t001
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Table 2. Meta-estimates for severe or critical COVID-19 compared to non-severe COVID-19.
Parameter Number of studies Number of persons Meta estimate (95% CI) p value Prediction interval I2 Q test p-value
Hematological parameters
White cell count
Continuous, MMD (×109/L) 28 4749 0.87 (0.35, 1.40) 0.001 -1.54, 3.30 80.5% <0.001
Without outlier studies 23 0.72 (0.36, 1.07) <0.001 -0.46, 1.89 45.8% 0.009
Leukocytosis, MPR 11 3455 3.95 (2.35, 6.65) <0.001 0.86, 18.22 64.3% 0.002
Without outlier studies 10 3.21 (2.13, 4.82) <0.001 1.18, 8.65 41.5% 0.081
Neutrophils
Continuous, MMD (×109/L) 21 3091 1.23 (0.58, 1.88) 0.001 -1.59, 4.05 89.9% <0.001
Without outlier studies 19 1.07 (0.71, 1.44) <0.001 -0.04, 2.18 46.0% 0.015
Neutrophilia, MPR 6 1237 4.29 (1.74, 10.64) 0.002 0.22, 84.80 85.6% <0.001
Lymphocytes
Continuous, MMD (×109/L) 27 6465 -0.38 (-0.46, -0.30) <0.001 -0.77, 0.01 84.0% <0.001
Without outlier studies 24 -0.38 (-0.45, -0.31) <0.001 -0.64, -0.12 57.3% 0.001
Lymphocytopenia, MPR 14 3875 1.74 (1.43, 2.12) <0.001 0.88, 3.42 92.5% <0.001
Without outlier studies 9 1.85 (1.47, 2.33) <0.001 0.97, 3.56 64.0% 0.005
Monocytes
Continuous, MMD (×109/L) 14 2002 -0.03 (-0.06, 0.01) 0.102 -0.14, 0.08 57.2% 0.004
Without outlier studies 13 -0.02 (-0.05, 0.01) 0.188 -0.11, 0.06 44.6% 0.041
Platelets
Continuous, MMD (×109/L) 24 3877 -21.47 (-41.12, -1.83) 0.032 -114.89, 71.94 92.0% <0.001
Without outlier studies 23 -18.95 (-28.52, -9.39) <0.001 -50.30, 12.38 47.9% 0.006
Thrombocytopenia, MPR 10 2421 1.79 (1.30, 2.48) <0.001 0.81, 3.98 48.4% 0.042
Hemoglobin
Continuous, MMD (g/dl) 17 2931 -0.33 (-0.57, -0.08) 0.010 -0.95, 0.30 32.5% 0.096
Without outlier studies 16 -0.31 (-0.53, -0.09) 0.005 -0.79, 0.17 21.2% 0.212
CD3 count
Continuous, MMD (cells/μl) 6 601 -380.82 (-515.30,
-246.36)
<0.001 -835.46, 73.80 80.1% <0.001
CD4 count
Continuous, MMD (cells/μl) 7 669 -204.86(-302.63, -107.10) <0.001 -539.07, 129.35 86.8% <0.001
CD8 count
Continuous, MMD (cells/μl) 6 600 -123.63 (-170.64,– 76.61) <0.001 -270.44, 23.19 66.2% 0.011
NLR
Continuous, MMD 5 1377 2.71 (1.82, 3.61) <0.001 -0.44, 5.87) 79.7% <0.001
SII
Continuous, MMD 2 487 394.00 (38.11, 749.87) 0.030 - 84.6% 0.010
Infection/inflammation-related
indices
C-reactive protein (CRP)
Continuous, MMD (mg/L) 26 4959 38.62 (29.16, 48.07) <0.001 -6.01, 83.23 88.4% <0.001
Without outlier studies 21 36.95 (29.30, 44.60) <0.001 9.36, 64.53 59.8% <0.001
Elevated CRP, MPR 13 2740 1.60 (1.32, 1.93) <0.001 0.78, 3.27 93.4% <0.001
Without outlier studies 11 1.59 (1.42, 1.77) <0.001 1.18, 2.13 53.9% 0.021
Erythrocyte sedimentation rate (ESR)
Continuous, MMD (mm/hr) 8 1705 20.01 (10.14, 29.87) <0.001 -13.27, 53.28 86.4% <0.001
Without outlier studies 7 15.4 (7.14, 23.73) <0.001 -11.09, 41.96 79.4% <0.001
Elevated ESR, MPR 3 545 1.67 (0.67, 4.17) 0.271 0.00, >100 97.9% <0.001
Interleukin-6 (IL6)
(Continued)
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Table 2. (Continued)
Parameter Number of studies Number of persons Meta estimate (95% CI) p value Prediction interval I2 Q test p-value
Continuous, MMD (pg/ml) 7 1183 17.37 (4.74, 30.00) 0.007 -24.70, 59.56 94.7% <0.001
Without outlier studies 6 20.61 (9.88, 31.33) <0.001 -13.45, 54.67 81.4% <0.001
Elevated IL6, MPR 3 357 2.15 (0.94, 5.00) 0.067 0.00, >100 87.4% <0.001
Without outlier studies 2 1.33 (1.07, 1.66) 0.001 - 0.0% 0.770
Procalcitonin (PCT)
Continuous, MMD (ng/ml) 18 4225 0.06 (0.04, 0.08) <0.001 -0.03, 0.15 89.5% <0.001
Without outlier studies 13 0.05 (0.04, 0.06) <0.001 0.03, 0.07 9.8% 0.348
Elevated PCT, MPR 12 2311 2.48 (1.78, 3.43) <0.001 0.99, 6.19 53.6% 0.014
Liver function parameters
Alanine aminotransferase (ALT)
Continuous, MMD (U/L) 25 4450 6.53 (4.43, 8.93) <0.001 1.09, 11.97 25.4% 0.122
Without outlier studies 21 5.21 (3.68, 6.73) <0.001 3.59, 6.82 0.0% 0.754
Elevated ALT, MPR 12 2540 1.59 (1.36, 1.87) <0.001 1.21, 2.09 10.3% 0.344
Aspartate aminotransferase (AST)
Continuous, MMD (U/L) 25 4320 11.95 (8.80, 15.11) <0.001 -0.04, 23.95 68.8% <0.001
Without outlier studies 22 10.63 (7.06, 14.19) <0.001 7.06, 14.19 11.8% 0.302
Elevated AST, MPR 14 2705 2.14 (1.80, 2.54) <0.001 1.43, 3.21 29.5% 0.141
Total bilirubin
Continuous, MMD (μmol/l) 18 2104 1.62 (0.87, 2.37) <0.001 0.81, 2.43 0.0% 0.490
Hyperbilirubinemia, MPR 5 1704 1.70 (1.23, 2.35) 0.001 1.01, 2.87 0.0% 0.699
Total protein
Continuous, MMD (g/L) 5 482 -1.49 (-3.19, 0.20) 0.085 -4.24, 1.26 0.0% 0.763
Hypoproteinemia, MPR 2 208 1.65 (1.33, 2.04) <0.001 - 0.0% 0.658
Albumin
Continuous, MMD (g/L) 21 2891 -4.58 (-6.21, -2.94) <0.001 -11.95, 2.79 95.4% <0.001
Without outlier studies 19 -4.27 (-5.21, -3.33) <0.001 -7.69, -0.85 67.9% <0.001
Hypoalbuminemia, MPR 4 554 2.23 (1.93, 2.93) <0.001 1.50, 3.77 0.0% 0.726
Prealbumin
Continuous, MMD (mg/dl) 3 367 -40.14 (-52.95, -27.33) <0.001 -133.59, 53.31 6.9% 0.342
Globulin
Continuous, MMD (g/L) 4 476 2.31 (0.58, 4.04) 0.009 -4.61, 9.22 63.2% 0.043
Without outlier studies 3 1.31 (0.30, 2.32) 0.011 -5.26, 7.88 0.0% 0.452
Kidney function parameters
Blood urea
Continuous, MMD (mmol/l) 19 2623 1.02 (0.66, 1.38) <0.001 -0.13, 2.17) 46.1% 0.015
Without outlier studies 18 1.09 (0.76, 1.42) <0.001 0.16, 2.02 36.1% 0.064
Elevated blood urea, MPR 3 624 3.63 (1.73, 7.65) <0.001 0.01, >100 39.9% 0.189
Creatinine
Continuous, MMD (μmol/l) 26 4467 5.57 (3.12, 8.03) <0.001 -0.43, 11.57 18.7% 0.197
Elevated creatinine, MPR 8 2019 1.90 (1.07, 3.36) 0.027 0.48, 7.43 40.5% 0.108
Cystatin C
Continuous, MMD (mg/l) 4 426 0.20 (0.10, 0.29) <0.001 -0.16, 0.55 52.8% 0.095
Myocardial biomarkers
Creatine kinase muscle-brain
Continuous, MMD (U/L) 10 1324 1.48 (0.36, 2.59) 0.009 -0.75, 3.71 19.6% 0.263
Continuous, MMD (ng/ml) 3 293 0.67 (0.19, 1.15) 0.007 -2.47, 3.18 0.0% 0.964
Troponin I
(Continued)
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likelihood of having leucocytosis (MPR: 3.95 [95% CI: 2.35, 6.65], I2: 64%) and neutrophilia
(MPR: 4.29 [95% CI: 1.74, 10.64], I2: 86%). All but one of 27 studies reported lower lymphocyte
Table 2. (Continued)
Parameter Number of studies Number of persons Meta estimate (95% CI) p value Prediction interval I2 Q test p-value
Continuous, MMD (ng/ml) 8 2379 0.02 (0.00, 0.04) 0.038 -0.03, 0.08 79.7% <0.001
Elevated Troponin I 3 831 4.00 (1.22, 13.2) 0.022 0.00, >100 85.8% 0.001
α-hydroxybutyric dehydrogenase
Continuous, MMD (U/L) 6 465 89.17 (45.26, 133.08) <0.001 -46.20, 224.55 67.6% 0.009
Other biochemical parameters
Glucose
Continuous, MMD (mmol/L) 7 1343 1.02 (0.64, 1.39) <0.001 0.20, 1.83 26.8% 0.224
Elevated glucose, MPR 2 491 1.40 (1.15, 1.72) 0.001 - 0.0% 0.411
Cholinesterase
Continuous, MMD (U/ml) 2 229 -1.11 (-1.79, -0.45) 0.001 - 0.0% 0.941
Lactate dehydrogenase (LDH)
Continuous, MMD (U/L) 22 2297 122.76 (94.14, 151.39) <0.001 8.83, 236.70 72.6% <0.001
Without outlier studies 20 114 (91.60, 138.21) <0.001 39.84, 189.97 49.6% 0.006
Elevated LDH, MPR 10 1893 2.41 (1.65, 3.51) <0.001 0.70, 8.34 87.7% <0.001
Without outlier studies 8 2.35 (1.65, 3.35) <0.001 0.77, 7.17 85.7% <0.001
Serum ferritin
Continuous, MMD (μg/L) 5 2342 430.28 (289.12, 571.45) <0.001 -5.40, 865.97 61.6% <0.001
Elevated ferritin, MPR 2 412 2.3 (1.67, 3.17) <0.001 - 0.0% 0.511
Serum electrolytes
Sodium
Continuous, MMD (mmol/L) 10 1503 -1.67 (-2.60, -0.74) 0.001 -3.98, 0.64 43.0% 0.072
Potassium
Continuous, MMD(mmol/L) 12 1790 -0.19 (-0.30, -0.10) <0.001 -0.46, 0.07 50.8% 0.022
Reduced potassium, MPR 3 667 1.70 (1.14, 2.54) 0.010 0.02, >100 58.5% 0.090
Chloride
Continuous, MMD(mmol/L) 6 1074 -1.49 (-3.08, 0.09) 0.065 -6.01, 3.03 57.5% 0.038
Calcium
Continuous, MMD(mmol/L) 5 486 -0.13 (-0.18, -0.09) <0.001 -0.26, -0.01 40.8% 0.149
Coagulation parameters
Prothrombin time
Continuous, MMD (s) 16 1650 0.39 (0.14, 0.64) 0.002 -0.44, 1.22 68.2% <0.001
Without outlier studies 15 0.29 (0.09, 0.48) 0.004 -0.22, 0.79 39.4% 0.058
Activated partial thromboplastin
Continuous, MMD (s) 14 1918 -0.49 (-1.95, 0.97) 0.509 -5.70, 4.72 77.6% <0.001
Without outlier studies 12 -0.33 (-1.50, 0.83) 0.575 -3.78, 3.11 55.2% 0.011
D-dimer
Continuous, MMD (mg/L) 23 4740 0.52 (0.37, 0.66) <0.001 -0.02, 1.05 82.4% <0.001
Without outlier studies 16 0.36 (0.27, 0.44) <0.001 0.27, 0.45 0.0% 0.561
Elevated D-Dimer, MPR 9 2030 2.27 (1.67, 3.09) <0.001 0.87, 5.92 76.9% <0.001
Without outlier studies 7 2.14 (1.81, 2.52) <0.001 1.72, 2.65 0.0% 0.435
A study was considered an outlier if the study’s confidence interval did not overlap with the confidence interval of the pooled effect.
MMD: meta-median difference; MPR: meta-prevalence ratio; NLR: neutrophil-to-lymphocyte ratio; SII: systemic inflammation Index; CRP: C-reactive protein; ESR:
erythrocyte sedimentation rate; IL-6: interleukin-6,; PCT: procalcitonin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; LDH: lactate dehydrogenase.
https://doi.org/10.1371/journal.pone.0239802.t002
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count in severe or critical COVID-19 patients relative to patients with non-severe disease.
Median difference in individual studies ranged from -0.8 to 0.2 (×109 cells/L). The MMD for
lymphocyte count (×109 cells/L) was -0.39 (95% -0.47, -0.31; I2: 78%), and the MPR for lym-
phopenia was 2.02 (95% CI: 1.52, 2.69; I2: 92%). Also, severe or critical COVID-19 patients
had relatively lower CD3 count (MMD: -380.8 [-515.3, -246.4], I2: 80%), CD4 count (MMD:
-204.9 [-302.6, -107.1], I2: 87%) and CD8 count (MMD: -123.6 [-170.6, -76.6] I2: 66%); all dif-
ferences measured in terms of cells/μl.
All studies that examined data on inflammation indices reported higher CRP, ESR and IL-6
level in severely or critically ill patients. Median difference in individual studies ranged from
8.1 to 83.3 mg/L for CRP, from 4.7 to 52.4 mm/hr for ESR, and from 1.1 to 101.4 pg/ml for IL-
6. The corresponding MMD (95% CI; I2) estimates were 36.97 (27.58, 46.35; 85%), 21.93
(10.59, 33.28; 88% for ESR, and 17.37 (4.74, 30.00; 95%) for IL-6. The MPR values for elevated
CRP, ESR and IL-6 were 1.50 [95% CI: 1.26, 1.77; I2: 91%), 1.67 (95% CI: 0.67, 4.18; I2: 98%)
and 2.15 (95% CI: 0.95, 4.90; I2: 87%), respectively, although the data for the last two parame-
ters were limited to just three studies. Higher levels of ferritin, a positive acute-phase reactant,
were positively associated with severe or critical COVID-19 (MMD: 451.86 μg/L [95% CI:
212.91, 690.82] I2: 71%), whereas the same association with albumin, a negative acute-phase
reactant, was in the opposite direction (MMD: -4.99 g/L [95% CI: -6.47, -3.51], I2: 87%).
Additional significant differences between patients with severe or critical COVID-19 and
their non-severely ill counterparts were observed for liver enzymes, ALT (MMD: 6.89 U/L [95%
CI; 4.69, 9.10], I2: 17%) and AST (MMD: 11.96 U/L [95% CI: 8.56, 15.37] I2: 68%); kidney func-
tion parameters, urea (MMD: 1.04 mmol/l [95% CI: 0.64, 1.45], I2: 48%) and creatinine (MMD:
4.87 μmol/l [95% CI: 2.40, 7.35], I2: 7%); biomarkers of myocardial function, troponin I (MMD:
0.01 ng/ml [95% CI: 0.00, 0.02], I2: 0%) and CK-MB (MMD: 1.46 U/L [95% CI:0.22, 2.70], I2:
28%); measures of coagulation, D-dimer (MMD: 0.65 mg/ml [95% CI: 0.45, 0.85], I2: 84%) and
platelet count (MMD: -21.48 ×109 cells/L [95% CI: -41.12, -1.83], I2: 92%); and lactate dehydro-
genase, a marker of tissue damage (MMD: 124.26 U/L [95% CI: 92.89, 155.64], I2: 74%).
Assessment of threats to validity
The threats to validity in this meta-analysis fall into two broad categories: risk of bias in indi-
vidual studies, and publication bias across the body of literature. Assessments of these two cat-
egories of threat to validity are presented below.
Using the NIH study quality assessment tools, 28 studies (62.2%) were rated as having a low
risk of bias, 14 studies (31.1%) were rated as having a medium risk of bias, and 3 studies (6.7%)
were rated as having a high risk of bias. The majority of studies had a clearly defined study
objective (97.8%), a well-defined study population (100%), and had comparable subjects
(100%). In contrast, no study provided a sample size calculation or power description. All the
studies were rated as having a high risk of bias for the element assessing a temporal sequence
between the laboratory measure and disease severity, and none of the reported results was
adjusted for potential confounding (Fig 2 and S5 Table in S1 File). Our results did not
markedly differ in sensitivity analyses after excluding studies with a high risk of bias.
The symmetry of funnel plots obtained from the 4 laboratory parameters with the highest
number of individual studies was assessed using Egger’s test. The symmetrical funnel plots for
C-reactive protein (p: 0.155) and creatinine (p: 0.415) suggested no evidence of publication
bias whereas asymmetrical funnel plot for white cell count (p: 0.004) and lymphocyte count (p:
0.005) indicated significant influence of smaller studies, which may be indicative of publication
bias (Fig 3). Important to note that Egger’s test may not be robust for C-reactive protein, white
cell count and lymphocyte parameters due to substantial heterogeneity (I2>75%).
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Additional analysis
In sensitivity analyses excluding outlier studies, statistical heterogeneity was reduced, and the
meta-estimate of most laboratory parameters were not markedly altered. In sensitivity analysis
using mean differences (S6 Table in S1 File), there was substantial heterogeneity for most labo-
ratory parameters, and the associations observed from using median differences persisted.
Discussion
COVID-19 is a rapidly evolving pandemic with significant global morbidity and mortality.
The aim of this meta-analysis was to investigate which clinical laboratory parameters may be
associated with severe or critical COVID-19 disease. Out of the 39 clinical laboratory parame-
ters evaluated, we found that derangements in 36 clinical laboratory parameters were
Fig 2. Summary plot for risk of bias assessment. A: Risk of bias assessment for 38 retrospective cohort/cross sectional studies; B: Risk of bias
assessment for 7 case series studies.
https://doi.org/10.1371/journal.pone.0239802.g002
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significantly associated with severe or critical COVID-19. Whilst some of the observed associa-
tions may not be clinically relevant, certain, more pronounced laboratory abnormalities may
have important clinical implications. Markers of an overactive innate immune system such as
markedly elevated neutrophil-to-lymphocyte ratio (NLR), IL-6, serum ferritin and C-reactive
protein, and markers of a deficient adaptive immune system such as lymphocytes and CD4
count could help recognise potential severe infections during triage, while markers of organ
failure could be helpful in monitoring evolution of hospitalised COVID-19 patients.
Following infection with a virus, the innate immune system in activated. This early
response is nonspecific and serves to limit virus multiplication during the acute phase [33].
The adaptive immune system is activated a few days later and is responsible for a more specific
response, which is immunomodulatory (via engagement of helper T cells and regulatory T
cells) and produces ‘immunological memory’ [33]. Elevated lymphocyte count is commonly
found in most viral infections, and the magnitude and quality of T cell responses may deter-
mine the fate of these infections [34, 35]. Failure to mount an appropriate adaptive immune
response means the innate immune response remains continuously stimulated with deleteri-
ous effects on the lungs and other organs. We found that severe or critical COVID-19 patients
had increased markers of innate immune system activity compared to patients with non-severe
disease. This is evidenced in the significantly higher levels of neutrophils, IL-6, and acute
phase reaction markers such as CRP, ESR and serum ferritin, as well as decreased concentra-
tions of albumin and prealbumin. Severe or critical COVID-19 patients also exhibited defec-
tive adaptive immune response evidenced by significantly lower levels of lymphocytes and
their subsets (CD3, CD4, CD8). CD4 count is currently being used to define severe cases of
HIV infection [36]. In the case of HIV, the virus directly infects CD4 cells using the envelope
Fig 3. Funnel plots. a: White cell count, Egger’s test, p = 0.004; b: Lymphocytes, Egger’s test, p = 0.005; c: C-Reactive protein, Egger’s test, p = 0.155; d: Creatinine,
Egger’s test, p = 0.415.
https://doi.org/10.1371/journal.pone.0239802.g003
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glycoprotein gp120. Various authors have suggested that SARS-CoV-2 could deplete lympho-
cytes directly by infecting T lymphocytes, or indirectly through lymphocyte apoptosis induced
by persistent elevated inflammatory cytokines [15, 37, 38]. Since severe COVID-19 patients
display reduced lymphocyte count, it is likely that the cytokine release syndrome observed in
some patients with severe or critical COVID-19 is mediated by interferons, TNFs, and cyto-
kines secreted by non-T cell leucocytes such as macrophages, neutrophils and NK cells which
are all key elements of innate immunity to viruses [39].
These findings could be applied clinically to identify severe or critical COVID-19 patients.
For example, routine monitoring of NLR may provide insight into the functioning of both the
innate and adaptive immune responses and help predict the clinical course of COVID-19.
Despite the 45 studies included in this review, only five reported results for NLR; all these five
studies found a significant association between increased NLR and severe or critical COVID-
19 disease.
We also found that patients with severe or critical COVID-19 had significantly higher bio-
markers of tissue and organ damage such as LDH, liver enzymes, kidney function parameters
and markers of myocardial function. These observed associations could be explained by 3
mechanisms. First, the virus may cause direct organ damage by attaching to the ACE2 recep-
tors, which are commonly expressed in the lungs, heart, arteries, kidneys and intestines [40].
The second, more indirect mechanism is systemic hyperinflammation caused by the cytokine
release syndrome mediated by the innate immune system [40]. Systemic hyperinflammation
affects all organs and could also explain the significantly increased expression of markers of
disseminated intravascular coagulation (high D-dimer and depleted platelet count) in severely
or critically ill patients [41, 42]. The third, also indirect, mechanism by which severe or critical
COVID-19 causes multiple organ damage is hypoxia resulting from respiratory failure.
Once the mechanisms of COVID-19 induced organ damage are better understood, markers
reflecting the pathophysiological changes caused by these mechanisms may find their way into
clinical practice. Based on the results of our meta-analysis especially promising may be mark-
ers of immune function such as NLR, IL-6, C-reactive protein, serum ferritin, lymphocytes,
CD4 count, and markers of coagulation and organ damage such as D-dimer, LDH, troponin I
and liver enzymes.
The strengths and limitations of this review and meta-analysis need to be considered in the
context of rapidly evolving literature. On the one hand, our study identified some associations
that deserve further consideration and may lead to improvements in the risk stratification,
monitoring and management of COVID-19 patients. On the other hand, it is important to
emphasize that our analyses need to be viewed as hypothesis-generating rather than hypothe-
sis-testing. Due to the large number of associations examined simultaneously there is a consid-
erable likelihood of false-positive findings. This limitation can be addressed in future, more
focused, studies that will take into consideration prior knowledge and reduce the likelihood of
false-positive results through application of Bayesian and empirical-Bayes methods [43]. Our
review is also affected by the limitations of the underlying literature. Of those, perhaps the
most important is the cross-sectional nature of the analyses used in most publications.
Although it is plausible that markers of immune function can be used to predict disease sever-
ity, the evidence would have been stronger if the studies were able to perform laboratory test-
ing of COVID-19 patients before their disease severity was known. In addition, many studies
from China reported on overlapping patient populations. While we tried to exclude studies
that relied on the same data, it is possible that some of the associations examined in this meta-
analysis were based on non-independent observations.
In conclusion, compared to non-severe COVID-19, severe or critical COVID-19 is associ-
ated with increased markers of innate immune response such as neutrophil count, NLR, IL-6,
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CRP and serum ferritin; decreased markers of adaptive immune response such as lymphocyte,
CD4 and CD8 counts; and increased markers of tissue damage and major organ failure includ-
ing D-dimer LDH, Troponin I, CK-MB, AST, ALT, urea, and creatinine. Based on the results
of our meta-analysis, especially promising markers are NLR, IL-6, serum ferritin, lymphocyte
and CD4 counts, D-dimer and troponin I. The clinical value of these markers should be
explored further to assess the risk of severe or critical disease and to monitor the clinical course
of COVID-19.
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